Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPC

Maha Hussain, MBChB, FACP, FASCO, of Northwestern University Feinberg School of Medicine, Chicago, IL, presents the results of the phase 3 PROfound study of olaparib vs. enzalutamide or abiraterone for metastatic castration-resistant prostate cancer HRR gene alterations. Next, Ignacio Duran, MD, PhD, Marques de Valdecilla University Hospital, Santander, Spain, discussing the impact of these data.